Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
NCT ID: NCT01151358
Last Updated: 2010-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2008-05-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
NCT05045664
Primary Rituximab and Maintenance
NCT00140582
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00278408
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
NCT00685997
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* finding of at least one image-guided measurable lymphoma lesion
* existence of FDG-PET- and CT-image data of at most 8 weeks before treatment
* signed patient´s agreement for RIT registry and MERIT-NHL
Exclusion Criteria
* solely CNS-lymphoma or primary effusion lymphoma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Saarland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital, Saarland
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carl-Martin Kirsch, MD
Role: PRINCIPAL_INVESTIGATOR
Universitaetsklinikum des Saarlandes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Nuclear Medicine, Saarland University Hospital
Homburg (Saar), Saarland, Germany
Klinikum Karlsruhe, Dept. of Nuclear Medicine
Karlsruhe, , Germany
University Clinic Kiel-Luebeck
Lübeck, , Germany
Technical University, Dept. of Nuclear Medicine
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cornelia Puskas, MD
Role: primary
Klemens Scheidhauer, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MERIT-NHL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.